Rapamune Approved for Rare Lung Disease
FRIDAY, May 29, 2015 (HealthDay News) -- Rapamune (sirolimus) has been approved by the U.S. Food and Drug Administration to treat a rare, progressive lung disease that mostly affects women of childbearing age.
Lymphangioleiomyomatosis (LAM) is characterized by the unusual growth of smooth-muscle cells among lung tissue. This can block normal airflow in the lungs and hinder delivery of oxygen to the rest of the body. The very rare disease affects only two to five women per million women globally, the FDA said in a news release.
The drug was first approved in 1999 to help prevent organ rejection among people aged 13 and older who had kidney transplant. It's now the first drug approved to treat LAM.
The FDA said it granted the drug's maker, Philadelphia-based Pfizer, financial incentives as part of a program to encourage development of medications to treat rare conditions.
The most common side effects reported during clinical testing included mouth and lip ulcers, diarrhea, abdominal pain, nausea, sore throat, acne and chest pain. More serious adverse effects included allergic-like reactions and swelling.
More information
Visit the FDA to learn more about this approval.
Related Articles
Search Allergy Articles
What Is Chronic Sinusitis, and How Is it Treated?
Spring Allergies Have Wide-Ranging Effects
Back-to-School Tips on Preventing Asthma, Allergy Flares in Kids
Healthy, Diverse Infant Microbiome Could Shield Kids From Asthma
American Air Is Getting Cleaner, But Benefits Aren't Reaching All
Dirty Air Increasingly Affects Minority Communities
Biden Administration to Tighten Air Pollution Standards
There Are Multiple Child Asthma Triggers in Dirty Air
Smoke From Wildfires Is Especially Tough If You Have Asthma. Here’s How to Protect Yourself
How Common Are Co-Infections With COVID, Flu, RSV?
Flu, COVID Cases Climb as RSV Infections Start to Level Off
Flu May Be Tougher on Brain Health Than COVID-19: Study
'Swine Flu' Strain Has Passed Between Humans & Pigs Hundreds of Times
Contrary to Popular Belief, 1918 Flu Did Not Target the Healthy Young